First patient randomised in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 EP News Bureau Sep 25, 2019 The trial is taking place for the treatment of Narcolepsy associated with or without Cataplexy in USA
Suven initiates MAD studies in phase 1 clinical trial for investigational compound SUVN-G3031 Usha Sharma Apr 13, 2015 SUVN-G3031 is a potent, selective, brain penetrant and orally active Histamine H3 inverse agonist being developed for the…
